Eagle Pharmaceuticals Inc (EGRX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9851)
◆英語タイトル:Eagle Pharmaceuticals Inc (EGRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9851
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Eagle Pharmaceuticals Inc (Eagle Pharma) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s commercial product portfolio encompasses pharmaceutical injectables, including Ryanodex for exertional heatstroke; Argatroban for thrombosis; diclofenac sodium misoprostol forosteoarthritis for rheumatoid arthritis; and docetaxel injection for oncology. Eagle pharma’s pipeline spans investigational candidates including Bendamustine RTD for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma; Bivalirudin for percutaneous transluminal angioplasty; and Pemetrexed for locally advanced or metastatic non-small cell lung cancer and mesothelioma. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in New Jersey, the US.

Eagle Pharmaceuticals Inc (EGRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Eagle Pharma Enters into R&D Agreement with United States Army Medical Research Institute of Chemical Defense 11
Eagle Pharma Enters into Agreement with National Institutes of Health 12
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 13
Arsia Therapeutics Enters into Research Agreement with Biogen 14
Eagle Pharma Enters into Agreement with Spectrum Pharma 15
Licensing Agreements 16
Symbio Pharma Enters into Licensing Agreement with Eagle Pharma 16
Eagle Pharma Enters into Licensing Agreement with Teikoku Pharma 17
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 18
Equity Offering 19
Eagle Pharma Raises USD54.3 Million in Public Offering of Shares 19
Eagle Pharma Completes IPO For US$50.3 Million 21
Asset Transactions 22
Eagle Pharma Divests Diclofenac for USD1.75 Million 22
Acquisition 23
Eagle Pharma Acquires Arsia Therapeutics 23
Eagle Pharmaceuticals Inc – Key Competitors 24
Eagle Pharmaceuticals Inc – Key Employees 25
Eagle Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 01, 2018: Eagle Pharmaceuticals reports third quarter 2018 results 27
Aug 07, 2018: Eagle Pharmaceuticals reports second quarter 2018 results 29
May 10, 2018: Eagle Pharmaceuticals Reports First Quarter 2018 Results 31
Feb 26, 2018: Eagle Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 33
Nov 08, 2017: Eagle Pharmaceuticals Reports Third Quarter 2017 Results 35
Aug 09, 2017: Eagle Pharmaceuticals Reports Second Quarter 2017 Results 37
May 08, 2017: Eagle Pharmaceuticals Reports First Quarter 2017 Results 39
Mar 01, 2017: Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 40
Corporate Communications 42
Sep 26, 2018: Eagle appoints David Pernock to position of Chief Operating Officer 42
May 15, 2017: Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer 43
Mar 16, 2017: Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors 44
Product Approvals 45
Mar 27, 2017: FDA Grants Priority Review for Eagle Pharmaceuticals Ryanodex NDA for the Treatment of Exertional Heat Stroke 45
Jan 23, 2017: Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eagle Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eagle Pharma Enters into R&D Agreement with United States Army Medical Research Institute of Chemical Defense 11
Eagle Pharma Enters into Agreement with National Institutes of Health 12
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 13
Arsia Therapeutics Enters into Research Agreement with Biogen 14
Eagle Pharma Enters into Agreement with Spectrum Pharma 15
Symbio Pharma Enters into Licensing Agreement with Eagle Pharma 16
Eagle Pharma Enters into Licensing Agreement with Teikoku Pharma 17
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 18
Eagle Pharma Raises USD54.3 Million in Public Offering of Shares 19
Eagle Pharma Completes IPO For US$50.3 Million 21
Eagle Pharma Divests Diclofenac for USD1.75 Million 22
Eagle Pharma Acquires Arsia Therapeutics 23
Eagle Pharmaceuticals Inc, Key Competitors 24
Eagle Pharmaceuticals Inc, Key Employees 25
Eagle Pharmaceuticals Inc, Subsidiaries 26

List of Figures
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Eagle Pharmaceuticals Inc (EGRX):製薬・医療:M&Aディール及び事業提携情報(Eagle Pharmaceuticals Inc (EGRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆